Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COCP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.21% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.45M USD | Price to earnings Ratio - | 1Y Target Price 8.33 |
Price to earnings Ratio - | 1Y Target Price 8.33 | ||
Volume (30-day avg) 19750 | Beta 2.35 | 52 Weeks Range 1.35 - 3.26 | Updated Date 04/2/2025 |
52 Weeks Range 1.35 - 3.26 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.84 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.53 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.98% | Return on Equity (TTM) -86.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3301781 | Price to Sales(TTM) 92.45 |
Enterprise Value 3301781 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 10173800 | Shares Floating 7012997 |
Shares Outstanding 10173800 | Shares Floating 7012997 | ||
Percent Insiders 31.85 | Percent Institutions 6.99 |
Analyst Ratings
Rating 4.5 | Target Price 8.33 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma, Inc. was founded in 2007. It focuses on discovering and developing novel antiviral therapeutics. It initially focused on creating new chemical entities (NCEs) through its structure-based drug design platform. Over time, it has shifted its focus to include other antiviral technologies.
Core Business Areas
- Antiviral Drug Discovery and Development: Cocrystal Pharma develops antiviral drugs using its structure-based drug design platform. Their focus areas are influenza, norovirus, and coronaviruses.
Leadership and Structure
The leadership team includes Sam Lee, PhD, as the co-founder and interim CEO. The company has a typical corporate structure with a board of directors overseeing operations.
Top Products and Market Share
Key Offerings
- CC-42344: CC-42344 is an oral protease inhibitor pan-influenza. This investigational drug is in development phase (Phase 1 complete). There is no market share data available as it is not approved for sale. Competitors include Roche (Tamiflu) and others developing influenza treatments.
- CC-42343: CC-42343 is a nucleoside analog influenza A inhibitor. This investigational drug is in development phase. There is no market share data available as it is not approved for sale. Competitors include Roche (Tamiflu) and others developing influenza treatments.
Market Dynamics
Industry Overview
The antiviral drug market is growing due to increasing prevalence of viral infections, advancements in drug development, and rising healthcare expenditure. The norovirus, influenza, and coronavirus segments are key areas of focus.
Positioning
Cocrystal Pharma is a small biotech company focusing on novel antiviral therapies. Its structure-based drug design platform is a competitive advantage, but it faces challenges due to its limited resources compared to larger pharmaceutical companies.
Total Addressable Market (TAM)
The global antiviral drug market is estimated at hundreds of billions of dollars. Cocrystal Pharma is positioned to capture a portion of this TAM with successful drug development, though its current TAM portion is low due to lack of commercialized products.
Upturn SWOT Analysis
Strengths
- Structure-based drug design platform
- Novel antiviral drug candidates
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other viral diseases
- Government funding for antiviral research
Threats
- Clinical trial failures
- Competition from established antiviral drugs
- Regulatory hurdles
- Market volatility in the biotech sector
Competitors and Market Share
Key Competitors
- MRK
- GILD
- JNJ
Competitive Landscape
Cocrystal Pharma's structure-based design may provide an advantage in developing novel drugs, but its small size and limited resources create a significant disadvantage when competing with larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on advancing drug candidates through clinical trials.
Future Projections: Future growth depends on clinical trial outcomes and securing partnerships. Analyst estimates are speculative due to the inherent risk in drug development.
Recent Initiatives: Focus on advancing their influenza and norovirus drug candidates through clinical trials.
Summary
Cocrystal Pharma is a development-stage biotech company with promising antiviral candidates. Its strength lies in its drug design platform. Its weaknesses lie in securing funding. Positive clinical trial results for their main candidates could lead to significant growth, while failures could jeopardize the company's future.
Similar Companies
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
RVMD
Revolution Medicines Inc
RVMD
Revolution Medicines Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information, and its accuracy is not guaranteed. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.cocrystalpharma.com |
Full time employees 12 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.